NEUROONE MEDICAL TECHNOLOGIES Corp (NMTC): auditor change — NeuroOne restates Q1 FY2026 results due to revenue recognition error; reaffirms FY2026 guidance

NEUROONE MEDICAL TECHNOLOGIES Corp

Revenue overstated by ~$0.5M, net loss understated by ~$0.3M for quarter ended March 31, 2026.
Restatement caused by customer order modification at quarter-end; no prior periods affected.
Company reaffirms FY2026 product revenue guidance of at least $10.5M.
Internal control weakness identified; measures to improve controls are being implemented.
Audit Committee determined non-reliance on previously filed Form 10-Q for March 31, 2026.

item 4.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Auditor Changes SEC 8-K Item 4.01/4.02 confidence 0.9

NEUROONE MEDICAL TECHNOLOGIES Corp reported that prior financial statements should not be relied upon.

Action: non reliance

Exact text from the filing

On May 21, 2026, the Audit Committee (the “Audit Committee”) of the Board of Directors of NeuroOne Medical Technologies Corporation (the “Company”), after discussion with management, determined that the Company’s previously issued interim financial statements included in the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, filed on May 12, 2026 (the “Previous Filing”), should no longer be relied upon and should be restated because of accounting errors relating to revenue recognition.

View on SEC.gov

8 auditor changes filed in the last 30 days. Browse all auditor changes →

NEUROONE MEDICAL TECHNOLOGIES Corp filing history →

Source: SEC EDGAR

accession 0001213900-26-060600

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.